Outcomes in COVID-19 cenicriviroc studies

0 0.5 1 1.5+ All studies -28% 3 1K Improvement, Studies, Patients Relative Risk Mortality -28% 3 1K Ventilation -167% 1 30 Hospitalization -17% 1 29 Recovery -2% 3 1K RCTs -28% 3 1K RCT mortality -28% 3 1K Late -28% 3 1K Cenicriviroc for COVID-19 c19early.org November 2025 Favorscenicriviroc Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] 64/355 49/354 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 mortality results c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kurth (DB RCT) -167% 2.67 [0.12-60.5] 1/18 0/12 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Late treatment -167% 2.67 [0.12-60.5] 1/18 0/12 167% higher risk All studies -167% 2.67 [0.12-60.5] 1/18 0/12 167% higher risk 1 cenicriviroc COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.55 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kurth (DB RCT) -17% 1.17 [0.80-1.69] hosp. time 17 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.42 Late treatment -17% 1.17 [0.80-1.69] 17 (n) 12 (n) 17% higher risk All studies -17% 1.17 [0.80-1.69] 17 (n) 12 (n) 17% higher risk 1 cenicriviroc COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.42 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 serious outcomes c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -14% 1.14 [0.81-1.59] no recov. 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -100% 2.00 [0.29-25.0] no recov. 17 (n) 12 (n) ACTIV-1 IM O’Halloran (DB RCT) 1% 0.99 [0.85-1.16] no recov. 360 (n) 363 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.82 Late treatment -2% 1.02 [0.88-1.17] 469 (n) 544 (n) 2% higher risk All studies -2% 1.02 [0.88-1.17] 469 (n) 544 (n) 2% higher risk 3 cenicriviroc COVID-19 recovery results c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.82 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 Randomized Controlled Trials c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] 64/355 49/354 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 RCT mortality results c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Late treatment -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk All studies -28% 1.28 [0.99-1.66] 65/465 49/535 28% higher risk 3 cenicriviroc COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.057 Effect extraction pre-specified(most serious outcome) Favors cenicriviroc Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -24% 1.24 [0.84-1.83] death 92 (n) 169 (n) Improvement, RR [CI] Treatment Control I-SPY COVID Files (RCT) -14% 1.14 [0.81-1.59] no recov. 92 (n) 169 (n) Kurth (DB RCT) -167% 2.67 [0.12-60.5] death 1/18 0/12 Kurth (DB RCT) -167% 2.67 [0.12-60.5] ventilation 1/18 0/12 Kurth (DB RCT) -500% 6.00 [0.34-107] oxygen 3/18 0/12 Kurth (DB RCT) -100% 2.00 [0.29-25.0] no recov. 17 (n) 12 (n) Kurth (DB RCT) -17% 1.17 [0.80-1.69] hosp. time 17 (n) 12 (n) ACTIV-1 IM O’Halloran (DB RCT) -30% 1.30 [0.93-1.83] death 64/355 49/354 ACTIV-1 IM O’Halloran (DB RCT) -16% 1.16 [0.79-1.71] death 49/355 42/354 ACTIV-1 IM O’Halloran (DB RCT) -8% 1.08 [0.81-1.41] no improv. 348 (n) 343 (n) ACTIV-1 IM O’Halloran (DB RCT) 1% 0.99 [0.85-1.16] no recov. 360 (n) 363 (n) Cenicriviroc COVID-19 outcomes c19early.org November 2025 Favors cenicriviroc Favors control